Dan-Dan Li1,2, Chang-Hao Zhao3, Huai-Wei Ding4, Qiong Wu1, Tian-Shu Ren1, Jian Wang4, Cong-Qin Chen1,5, Qing-Chun Zhao1. 1. Department of Pharmacy, General Hospital of Shenyang Military Area Command, Shenyang, China. 2. Department of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China. 3. College of Pharmacy, The Heilongjiang University of Traditional Chinese Medicine, Heilongjiang, China. 4. Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China. 5. Department of Pharmacy, Longyan First Hospital, Fujian Medical University, Longyan, China.
Abstract
OBJECTIVES: Colorectal cancer is one of the most common malignancies both in men and women. Owing to metastasis and resistance, the prognosis of colorectal cancerCRC patients remains extremely poor with chemotherapy. A disintegrin and metalloproteinase 17 (ADAM17) induces the activation of Notch pathway and contributes to the chemoresistance. This study aimed to discover a novel ADAM17 inhibitor and investigate the chemosensitization effect. MATERIALS AND METHODS: Pharmacophore model, western blot and enzymatic assay were used to discover ZLDI-8. Cell proliferation was determined by MTT and colony formation assay. Cell migratory and invasive ability were determined by wound healing scratch and transwell assay. Immunofluorescence images and western blot analysed the expression of Notch or epithelial-mesenchymal transition (EMT) pathway markers. Xenografts were employed to evaluate the chemosensitization effect of ZLDI-8 in vivo. RESULTS: We found that ZLDI-8 cell-specifically inhibited the proliferation of CRC, and this effect was due to abrogation of ADAM17 and Notch pathway. Meanwhile, we reported for the first time that ZLDI-8 synergistically improved the anti-tumour and anti-metastasis activity of 5-fluorouracil or irinotecan by reversing Notch and EMT pathways. Interestingly, in vivo studies further demonstrated that ZLDI-8 promoted the anti-tumour effect of 5-fluorouracil through Notch and EMT reversal. CONCLUSIONS: A novel ADAM17 inhibitor ZLDI-8 may be a potential chemosensitizer which sensitized CRC cells to 5-fluorouracil or irinotecan by reversing Notch and EMT pathways.
OBJECTIVES:Colorectal cancer is one of the most common malignancies both in men and women. Owing to metastasis and resistance, the prognosis of colorectal cancerCRCpatients remains extremely poor with chemotherapy. A disintegrin and metalloproteinase 17 (ADAM17) induces the activation of Notch pathway and contributes to the chemoresistance. This study aimed to discover a novel ADAM17 inhibitor and investigate the chemosensitization effect. MATERIALS AND METHODS: Pharmacophore model, western blot and enzymatic assay were used to discover ZLDI-8. Cell proliferation was determined by MTT and colony formation assay. Cell migratory and invasive ability were determined by wound healing scratch and transwell assay. Immunofluorescence images and western blot analysed the expression of Notch or epithelial-mesenchymal transition (EMT) pathway markers. Xenografts were employed to evaluate the chemosensitization effect of ZLDI-8 in vivo. RESULTS: We found that ZLDI-8 cell-specifically inhibited the proliferation of CRC, and this effect was due to abrogation of ADAM17 and Notch pathway. Meanwhile, we reported for the first time that ZLDI-8 synergistically improved the anti-tumour and anti-metastasis activity of 5-fluorouracil or irinotecan by reversing Notch and EMT pathways. Interestingly, in vivo studies further demonstrated that ZLDI-8 promoted the anti-tumour effect of 5-fluorouracil through Notch and EMT reversal. CONCLUSIONS: A novel ADAM17 inhibitor ZLDI-8 may be a potential chemosensitizer which sensitized CRC cells to 5-fluorouracil or irinotecan by reversing Notch and EMT pathways.
Authors: Robert D Mazzola; Zhaoning Zhu; Lisa Sinning; Brian McKittrick; Brian Lavey; James Spitler; Joseph Kozlowski; Shih Neng-Yang; Guowei Zhou; Zhuyan Guo; Peter Orth; Vincent Madison; Jing Sun; Daniel Lundell; Xiaoda Niu Journal: Bioorg Med Chem Lett Date: 2008-09-13 Impact factor: 2.823
Authors: J I Levin; J M Chen; L M Laakso; M Du; J Schmid; W Xu; T Cummons; J Xu; G Jin; D Barone; J S Skotnicki Journal: Bioorg Med Chem Lett Date: 2006-01-19 Impact factor: 2.823
Authors: Wensheng Yu; Ling Tong; Seong Heon Kim; Michael K C Wong; Lei Chen; De-Yi Yang; Bandarpalle B Shankar; Brian J Lavey; Guowei Zhou; Aneta Kosinski; Razia Rizvi; Dansu Li; Robert J Feltz; John J Piwinski; Kristin E Rosner; Neng-Yang Shih; M Arshad Siddiqui; Zhuyan Guo; Peter Orth; Himanshu Shah; Jing Sun; Shelby Umland; Daniel J Lundell; Xiaoda Niu; Joseph A Kozlowski Journal: Bioorg Med Chem Lett Date: 2010-07-01 Impact factor: 2.823
Authors: Kaitlyn E Vinson; Dennis C George; Alexander W Fender; Fred E Bertrand; George Sigounas Journal: Int J Cancer Date: 2015-08-27 Impact factor: 7.396
Authors: Samarpan Majumder; Judy S Crabtree; Todd E Golde; Lisa M Minter; Barbara A Osborne; Lucio Miele Journal: Nat Rev Drug Discov Date: 2020-12-08 Impact factor: 84.694
Authors: Jose J G Marin; Rocio I R Macias; Maria J Monte; Elisa Herraez; Ana Peleteiro-Vigil; Beatriz Sanchez de Blas; Paula Sanchon-Sanchez; Alvaro G Temprano; Ricardo A Espinosa-Escudero; Elisa Lozano; Oscar Briz; Marta R Romero Journal: Cancers (Basel) Date: 2020-09-11 Impact factor: 6.639